Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB1908 in Advanced Gastric, GEJ, Esophageal, or Pancreatic Adenocarcinoma
NCT05539430Phase 1Active, not recruiting
- Sponsor
- Legend Biotech Corporation
- Start
- Apr 2023
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LCAR-C18S in gastric cancer (GC), gastroesophageal junction cancer, esophageal cancer and 1 more, sponsored by Legend Biotech Corporation. Primary endpoints: Safety and tolerability of LB1908 and determination of the recommended dose for expansion (RDE) at 2 years and Safety and tolerability of LB1908 and determination of the recommended Phase 2 dose (RP2D) at 2 years. Started Apr 2023; status: active, not recruiting.
02
Drugs
LCAR-C18S
03
Conditions
gastric cancer (GC)gastroesophageal junction canceresophageal cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05539430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05539430.